预约演示
更新于：2026-07-31
Forimtamig
更新于：2026-07-31
概要
基本信息
原研机构- |
非在研机构- |
权益机构- |
最高研发阶段临床1/2期 |
首次获批日期- |
最高研发阶段(中国)临床申请批准 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 565381979
来源: *****
Sequence Code 565382263
来源: *****
Sequence Code 682564950
来源: *****
Sequence Code 682564951
来源: *****
关联
2
项与 Forimtamig 相关的临床试验NCT06055075
An Open-Label, Randomized Phase IB/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557150
An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig (RO7425781) in Participants With Relapsed or Refractory Multiple Myeloma
100 项与 Forimtamig 相关的临床结果
登录后查看更多信息
100 项与 Forimtamig 相关的转化医学
登录后查看更多信息
100 项与 Forimtamig 相关的专利（医药）
登录后查看更多信息
7
项与 Forimtamig 相关的文献（医药）2026-06-01Annals of Medicine and Surgery
Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma
作者: Asad, Maham ; Ali, Hafsa ; Hilal, Hiba ; Jaber Amin, Mohammed Hammad ; Gul, Maliha
Multiple myeloma is a malignancy of clonal plasma cells characterized by progressive bone marrow infiltration, commonly presenting with anemia, bone pain, hypercalcemia, and renal dysfunction. T-cell bispecific antibodies (TCBs) have emerged as an effective therapeutic option in relapsed and refractory multiple myeloma, with G-coupled protein receptor, family C, group 5, member D (GPRC5D) representing a promising target due to its high expression in myeloma cells and limited presence in normal tissues. Forimtamig is a next-generation GPRC5D-targeting TCB with a novel 2:1 binding format – bivalently engaging GPRC5D and monovalently binding CD3ε on T cells. This structural advantage enhances avidity, stabilizes immunological synapses, and enables potent T-cell activation and cytotoxicity, even against low-antigen-expressing cells in immunosuppressive bone marrow environments. Preclinical studies show that forimtamig outperforms earlier 1 + 1 TCB formats by 50–200-fold in cell-killing efficiency. When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Its design also minimizes tumor escape by targeting the N-terminal region of GPRC5D. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
2025-12-31mAbs
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice
Article
作者: Lechner, Stefanie ; Crisand, Cylia ; Bröske, Ann-Marie E. ; Osl, Franz ; Attig, Jan ; Colombetti, Sara ; Mueller, Joerg P.J. ; Klein, Christian ; O’Brien, Nils ; Beilhack, Andreas ; Eckmann, Jan ; Wolf, Ann-Katrin ; Pöschinger, Thomas ; Rae, Richard ; Umaña, Pablo
T cell bispecific antibodies (TCBs) are a promising new class of therapeutics for relapsed/refractory multiple myeloma. A frequently observed, yet incompletely understood effect of this treatment is the transient reduction of circulating T cell counts, also known as T cell margination (TCM). After administration of the GPRC5D-targeting TCB forimtamig (RG6234), TCM occurred in patients and correlated with cytokine release and soluble B cell maturation antigen decrease. We demonstrate that TCM is accurately represented in the humanized NSG mouse model and occurs at a lower threshold of target expression than systemic cytokine release. Application of whole-mouse tissue clearing and 3D imaging revealed that T cells accumulate in the bone marrow after treatment. We hypothesize that low amounts of targets are sufficient to rapidly redirect T cells upon TCB engagement. Therefore, we propose TCM as a beneficial, highly sensitive and early effect of forimtamig that leads T cells to likely sites of bone marrow tumor lesions.
2025-05-01Clinical Lymphoma Myeloma & Leukemia
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives
Review
作者: Rasche, Leo ; Einsele, Hermann ; Waldschmidt, Johannes M ; Kortüm, K Martin
Despite significant advancements, multiple myeloma (MM) remains incurable, and there is still a pressing need for new therapeutic strategies with highly selective mechanisms of action and balanced off-target toxicity. In recent years, the development of "off-the-shelf" bispecific antibodies (bsAbs) has significantly enhanced our ability to treat relapsed or refractory MM. Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Meanwhile, the range of available bsAbs is rapidly expanding, offering patients and healthcare providers a broad selection of options that vary in target antigens, binding domains, construct designs, dosing regimens, and side effects. As linvoseltamab, alnuctamab, and ABBV-383 (all BCMA × CD3), as well as forimtamig (GPRC5D × CD3) and cevostamab (FcRH5 × CD3) progress through late-stage clinical development, emerging trispecific antibodies are now available that target either 2 different MM-associated antigens or provide additional co-stimulatory signals to prevent T-cell exhaustion. Despite this plethora of therapeutic options, resistance to bsAbs is an inevitability, and the optimal positioning of these drugs within the current MM treatment landscape remains to be determined. In this review, we examine the available data on all clinically accessible bsAbs, evaluating their potential, current limitations, and implications for efficacy and safety, with the aim of achieving deeper responses and longer overall survival for MM patients.
100 项与 Forimtamig 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性多发性骨髓瘤 | 临床2期 | 澳大利亚 | 2023-12-12 | |
| 难治性多发性骨髓瘤 | 临床2期 | 加拿大 | 2023-12-12 | |
| 难治性多发性骨髓瘤 | 临床2期 | 意大利 | 2023-12-12 | |
| 难治性多发性骨髓瘤 | 临床2期 | 新西兰 | 2023-12-12 | |
| 难治性多发性骨髓瘤 | 临床2期 | 韩国 | 2023-12-12 | |
| 难治性多发性骨髓瘤 | 临床2期 | 西班牙 | 2023-12-12 | |
| 复发性多发性骨髓瘤 | 临床1期 | 澳大利亚 | 2020-11-11 | |
| 复发性多发性骨髓瘤 | 临床1期 | 比利时 | 2020-11-11 | |
| 复发性多发性骨髓瘤 | 临床1期 | 丹麦 | 2020-11-11 | |
| 复发性多发性骨髓瘤 | 临床1期 | 法国 | 2020-11-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 163 | 鬱鑰鏇廠夢範遞淵繭簾(範憲獵顧積艱餘夢簾壓) = 鑰鏇膚鬱夢衊願範範齋 鏇醖獵網膚襯窪繭繭積 (憲積鹹淵顧築窪網醖廠, 0 ~ 100) 更多 | - | 2023-12-09 | |||
临床1期 | 120 | 顧選鏇衊積網願鬱蓋遞(構廠鑰糧網遞壓積鹹鏇) = 遞遞製夢壓醖憲積範遞 膚蓋願獵簾窪膚鹹願膚 (窪糧簾製襯鏇壓艱壓鹽 ) 更多 | - | 2023-09-26 | |||
临床1期 | 105 | (Intravenous) | 鑰獵艱壓遞衊夢鬱廠餘(鑰構繭窪襯觸積積襯壓) = Gr ≥3 hematologic AEs were infrequent (anemia: IV 13.7%, SC 5.2%; thrombocytopenia: IV 13.8%, SC 18.5%; neutropenia: IV 11.8%, SC 16.7%) 窪糧餘衊網窪鹹顧繭願 (蓋觸齋遞蓋鑰窪範窪遞 ) 更多 | 积极 | 2022-11-15 | ||
(Subcutaneous) | |||||||
临床1期 | 41 | 鏇繭糧淵築鹽壓艱繭觸(餘蓋醖憲齋夢網憲齋製) = CRS occurred in 85.4% of pts (G1 56.1%, G2 24.4%, G3 2.4%). Three pts (7.3%) experienced CNS toxicity related to RG6234 (G1 and G3 headache; G1 confusion). G3/4 neutropenia, thrombocytopenia, and anemia occurred in 9.8%, 19.5%, and 12.2% of pts, respectively. 糧蓋製鑰選齋鹹築蓋選 (憲觸鏇簾糧製願襯鹹構 ) 更多 | 积极 | 2022-05-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用